Verici Dx (VRCI) H1 2026 earnings summary

Executive summary

• Achieved $1.8m in revenue for H1 2026, with Tutivia testing revenues up 53% year-over-year and 32 transplant centers onboarded by June, expanding to 35 by report date.

• Equity fundraise in June 2026 raised gross proceeds of £2.6m ($3.4m), with a further proposed raise announced to support growth.

• Tutivia now represents 23% of annual US kidney transplants, with average reimbursement of $2,300 per test.

• Protega test granted a CPT® PLA code, effective October 2026, supporting future commercialization.

Financial highlights

• Revenue of $1.8m in H1 2026 (H1 2025: $1.9m), with Tutivia revenue up 51.2% year-over-year.

• Adjusted EBITDA loss of $3.5m (H1 2025: $2.8m loss); net loss of $4.0m (H1 2025: $3.1m loss).

• Cash balance of $2.4m at 30 June 2026 (31 Dec 2025: $3.3m); net cash outflow from operations $3.8m.

• Accounts receivable increased to $2.1m, reflecting higher revenues and longer embedding into payor systems.

Outlook and guidance

• Q3 2026 test orders expected to exceed 500, with nine-month growth over 53% year-over-year.

• Anticipates further strong growth in Q4 2026 from expanded sales team and new centers.

• New product Transcriptx to launch by end FY 2026, with Protega and PTRA expected to generate revenue in FY 2027.